management, non-small cell lung cancer, staging.The treatment of non-small cell lung cancer (NSCLC) depends on staging based on tumour (T), nodal (N) and metastasis (M) descriptors. Stages I and II tumours are potentially curable with surgery alone. Stage IIIA T3 tumours are also ...
small-cell lung cancer.Advanced non–small-cell lung cancer (NSCLC) remains an incurable disease despite significant progress in chemotherapy. We conducted a phase II clinical trial to investigate the efficacy and toxicity of a cisplatin, etoposide, and 5-fluorouracil (5-FU) combination in advanced...
No study left behind: a network meta-analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant data. Value Health 2009;12:996-1003.Hawkins N, Scott DA, Woods BS, Thatcher N. 2009b. No study left behind: a network meta-analysis in non-small-cell lung...
Non-small-cell lung cancer (NSCLC) is one of the most common malignancies and the leading causes of cancer-related death worldwide. Despite many therapeutic advances in the past decade, NSCLC remains an incurable disease for the majority of patients. Molecular targeted therapies and immunotherapies...
Non-small cell lung cancer is predominantly a disease of older people in whom treatment intolerance is common. To make well-informed shared decisions concerning treatment options, pretreatment screening and/or assessment might be useful to identify patients who are expected to benefit from preventive ...